Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of deferasirox dose adjustment by serum ferritin in transfusional iron overload
2006-003337-32Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in transfusional hemosiderosis and hemosiderosis, sponsored by Novartis. Primary endpoint: Change in liver iron concentration. Started Mar 2010; status: completed.
02
Drugs
deferasirox
03
Conditions
transfusional hemosiderosishemosiderosis
Beyond the preview
Go deeper on 2006-003337-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003337-32.